BridgeBio Pharma earnings

Next report

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 29, 2025 and Nov 12, 2024, after the close.

Who else reports that week: the earnings calendar.

Last report: Aug 10, 2026, 20:03 ET (after the close). The filing on SEC EDGAR ↗

Across the last 5 reports we hold closes for, the first close moved a median 2.59% either way. Up 1 of 5.

Moves are only shown for reports where we hold closing prices.

1. Aug 10, 202620:03 ET · after the close8-K ↗−1.15%1DRevenue $243.7M+120.4% y/yEPS −$0.78quarter to Jun 30, 2026
2. May 7, 202620:02 ET · after the close8-K ↗−0.09%1DRevenue $194.5M+66.8% y/yEPS −$0.84quarter to Mar 31, 2026
3. Feb 24, 202621:04 ET · after the close8-K ↗−2.59%1DRevenue $154.2M+2521.2% y/yquarter to Dec 31, 2025
4. Jan 12, 202621:06 ET · after the close8-K ↗+2.95%1DRevenue $154.2M+2521.2% y/yquarter to Dec 31, 2025
5. Oct 29, 202520:02 ET · after the close8-K ↗−4.88%1DRevenue $120.7M+4318.0% y/yEPS −$0.95quarter to Sep 30, 2025
6. Before Sep 2, 2025 we don't hold closing prices, so these reports show the date and what was filed, without a move.
7. Aug 5, 202520:04 ET · after the close8-K ↗Revenue $110.6M+4999.9% y/yEPS −$0.95quarter to Jun 30, 2025
8. Apr 29, 202520:04 ET · after the close8-K ↗Revenue $116.6M−44.8% y/yEPS −$0.88quarter to Mar 31, 2025
9. Feb 20, 202512:31 ET · during the session8-K ↗Revenue $5.88M+237.1% y/yquarter to Dec 31, 2024
10. Nov 12, 202412:31 ET · during the session8-K ↗Revenue $2.73M−33.2% y/yEPS −$0.86quarter to Sep 30, 2024
11. Aug 1, 202411:31 ET · during the session8-K ↗Revenue $2.17M+32.1% y/yEPS −$0.39quarter to Jun 30, 2024
12. May 2, 202411:31 ET · during the session8-K ↗Revenue $211.1M+11461.9% y/yEPS −$0.20quarter to Mar 31, 2024
13. Feb 22, 202412:31 ET · during the session8-K ↗Revenue $1.75M−6.7% y/yquarter to Dec 31, 2023
14. Nov 2, 202311:31 ET · during the session8-K ↗Revenue $4.09M+1110.4% y/yEPS −$1.08quarter to Sep 30, 2023
15. Aug 3, 202311:32 ET · during the session8-K ↗Revenue $1.64M−97.8% y/yEPS −$0.98quarter to Jun 30, 2023
16. May 4, 202311:46 ET · during the session8-K ↗Revenue $1.83M+7.8% y/yEPS −$0.92quarter to Mar 31, 2023

Move = the first close after the release against the close before it. A release after 4pm ET is priced by the next session; one before 9:30am ET by that day’s. Times are when the SEC accepted the 8-K (Item 2.02), which follows the press release by minutes. Closes held from Sep 2, 2025; “no price data” means we don't hold the closes for that report. 1 other Item 2.02 filing, filed weeks ahead of a report (a delivery or preliminary update), is not counted as a report. Prior-session closes only; not a forecast, not advice.